NewAmsterdam Pharma Presents Additional Data from Pivotal Phase 3 BROOKLYN Clinical Trial Evaluating Obicetrapib in Patients with Heterozygous Familial Hypercholesterolemia at AHA Scientific Sessions 2024
At the American Heart Association (AHA) Scientific Sessions 2024, NewAmsterdam Pharma presented compelling new data from its pivotal Phase 3 BROOKLYN clinical trial, which evaluated the efficacy and safety of Obicetrapib in patients with heterozygous familial hypercholesterolemia (HeFH). The trial results indicate that Obicetrapib has met its primary endpoint, demonstrating a mean reduction in low-density lipoprotein cholesterol (LDL-C) of 36.3% at day 84 and an impressive 41.5% at day 365, compared to a placebo group.
These results mark a significant advancement in the treatment of HeFH, a genetic disorder that can lead to dangerously high cholesterol levels and increased risk of cardiovascular disease. We are excited to see the robustness of Obicetrapib s performance over the trial duration, said NewAmsterdam Pharma’s Chief Medical Officer. These findings reinforce our commitment towards providing innovative solutions for patients struggling with high cholesterol.
In addition to these clinical advancements, NewAmsterdam Pharma reported a significant shift in its financial standing, with its leverage ratio dropping to 0.16 following net new borrowings of 1.93%. This figure represents a notable improvement compared to the previous leverage ratio of 0.15 reported in the second quarter of 2024. In the context of the biopharmaceutical industry, NewAmsterdam Pharma now ranks higher with respect to leverage ratio than 53 other companies that reported lower figures during the third quarter of 2024.
The past twelve months have seen the company s leverage ratio decrease by 0.17, reaching a new all-time low. This reduction, fueled by consistent repayments of liabilities, reinforces NewAmsterdam Pharma’s strong financial position as it continues to advance its clinical development programs.
We are not only focused on delivering promising therapies for patients but also on maintaining a strong financial health that supports our long-term growth strategy, the company’s CEO stated at the conference. Our efforts to reduce our leverage ratio reflect our commitment to financial discipline and sustainable development.
With promising clinical trial results and improved financial metrics, NewAmsterdam Pharma is poised for significant impact in the biopharmaceutical sector, targeting critical unmet needs in cholesterol management and cardiovascular health. As the company continues to explore the full potential of Obicetrapib, stakeholders remain optimistic about the future of their innovative treatment solutions.
Comments